2月12日 - ** PTC Therapeutics PTCT.O盘后股价下跌5.2%至67.05美元
** 该公司称已撤回其肌肉失调药物Translarna的重新上市申请
** PTCT表示："FDA认为，根据其迄今为止的审查结果，NDA呈文中的数据不太可能达到该机构关于支持批准Translarna的实质性有效性证据的门槛"。
** 去年，该公司表示，由于欧盟委员会决定不再延长 Translarna 的上市许可，该药将不再在欧盟销售。
** 该药旨在促进一种名为肌营养不良蛋白（dystrophin）的蛋白质的生成，缺乏这种蛋白质会导致杜兴氏肌肉萎缩症患者的肌肉变弱。
** 2025 年 PTCT 增长了 68.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.